Press release
Metastatic Prostate Cancer Market to Record 8.4% CAGR Growth Through 2029 | Global Analysis Report
Metastatic Prostate Cancer
Metastatic Prostate Cancer Market Outlook: How is the Market Expected to Grow by 2025?
The market for metastatic prostate cancer has seen a robust growth in its size in the past few years. The growth trajectory indicates an increase from $8.11 billion in 2024 to $8.81 billion in 2025, showing a compound annual growth rate (CAGR) of 8.7%. Factors affecting this growth during the historic timeframe include an increase in the elderly population, a rise in cases of prostate cancer, improved awareness and screening initiatives, enhanced diagnostic techniques, and escalated healthcare spending.
Metastatic Prostate Cancer Market Forecast: What Size Will It Reach By 2029?
The market size for metastatic prostate cancer is poised to experience robust growth in the upcoming years, reaching a value of $12.16 billion by 2029 with a compound annual growth rate (CAGR) of 8.4%. The projected growth in the forecast period is based on factors such as increased screening efforts, beneficial insurance reimbursement policies, the surge in the implementation of advanced treatment methods, and market growth in developing markets. The trend forecast for this period also highlights advances in diagnostic imaging technology, breakthroughs in targeted treatments, progress in liquid biopsy research, immunotherapy development, and the growing use of minimally invasive surgical procedures.
Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/metastatic-prostate-cancer-global-market-report
Which Key Market Drivers Will Shape Metastatic Prostate Cancer Industry Trends in 2025-2029?
The metastatic prostate cancer market is predicted to advance due to the increasing desire for customized therapies. Customized treatments, which are designed based on an individual's unique genetic makeup, lifestyle factors, and particular disease traits, promise more precise and successful results. This growing appeal can be traced back to the burgeoning availability of genomic profiling and biomarker testing. These technological advancements aid in detecting unique mutations and biological markers, enabling medical practitioners to opt for remedies that are likely to be more effective for each person. Personalized therapy methods, including biomarker-informed treatments and gene-targeted medications, are overhauling the management of metastatic prostate cancer by aligning specific treatments with each patient's distinct tumor profile. This, in turn, boosts effectiveness and reduces potential side effects. For instance, the Personalized Medicine Coalition, a non-profit-based organization in the U.S., noted in February 2024 that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023 as opposed to just 6 in 2022. Consequently, the escalating demand for such individualized treatments is fueling the growth of the metastatic prostate cancer market.
Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25833&type=smp
What Are the High-Growth Segments in the Metastatic Prostate Cancer Market?
The metastatic prostate cancer market covered in this report is segmented -
1) By Treatment Type: Chemotherapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Other Treatments
2) By Route of Administration: Oral, Parenteral Route, Intravenous, Intrathecal, Intraperitoneal, Intra-Arterial, Topical
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End User: Hospitals, Clinics, Cancer Centers, Research Laboratories, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens
2) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapies
3) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors, Combined Androgen Blockade (CAB)
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiotherapy (SBRT), Radiopharmaceutical Therapy, Intensity-Modulated Radiation Therapy (IMRT)
5) By Other Treatments: Targeted Therapy, Bone-Targeted Therapy, Clinical Trial Drugs, Palliative Therapy
Which Global Trends Are Driving Metastatic Prostate Cancer Market Expansion?
Major companies operating in the metastatic prostate cancer market are focusing on developing advanced treatment approaches such as targeted radioligand therapy to enhance treatment specificity, minimize damage to healthy tissues, and improve patient outcomes. Targeted radioligand therapy is an advanced form of precision cancer treatment that combines a molecule designed to target specific cancer cells (ligand) with a radioactive isotope that delivers localized radiation to destroy those cells. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceuticals and healthcare solutions company, received US Food and Drug Administration (FDA) approval for Pluvicto, the first targeted radioligand therapy for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. It features lutetium-177, a radioactive isotope, linked to a ligand that targets PSMA, a protein found in high levels on prostate cancer cells, enabling precise delivery of radiation. Pluvicto represents a breakthrough in prostate cancer care by significantly extending progression-free survival in patients who have exhausted other treatment options.
Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25833&type=smp
Who Are the Fastest-Growing Companies in the Metastatic Prostate Cancer Industry?
Major companies operating in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Zenith Epigenetics Ltd., Tavanta Therapeutics Inc., Cardiff Oncology Inc., Oncternal Therapeutics Inc., Clarity Pharmaceuticals Ltd., Convergent Therapeutics Inc.
What Is the Regional Outlook for the Metastatic Prostate Cancer Market by 2029?
North America was the largest region in the metastatic prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Prostate Cancer Market to Record 8.4% CAGR Growth Through 2029 | Global Analysis Report here
News-ID: 4157206 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
